Vasilios Pergialiotis1,2, Ioanna Myrto Sotiropoulou3, Efstathia Liatsou3, Michalis Liontos4, Maximos Frountzas3, Nikolaos Thomakos5, Alexandros Rodolakis5, Dimitrios Haidopoulos5. 1. 1st Department of Obstetrics and Gynecology, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece. pergialiotis@yahoo.com. 2. Laboratory of Experimental Surgery and Surgical Research N.S Christeas, National and Kapodistrian University of Athens, 6, Danaidon Str., 15232, Halandri, Greece. pergialiotis@yahoo.com. 3. Laboratory of Experimental Surgery and Surgical Research N.S Christeas, National and Kapodistrian University of Athens, 6, Danaidon Str., 15232, Halandri, Greece. 4. Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece. 5. 1st Department of Obstetrics and Gynecology, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Abstract
PURPOSE: Chemotherapy is the cornerstone of adjuvant therapy in ovarian cancer. Its impact on the quality of life (QoL) has been addressed in several studies; however, several misperceptions concerning this affect patient counseling and physicians' ability to overcome patient fears. In the present systematic review, we sought to accumulate current evidence in the field in order to help establish robust information that will help physicians answer patients' questions. METHODS: The present systematic review is based on the PRISMA guidelines. Studies that evaluated patient QoL pre-, during, and post-chemotherapy with the use of the QLQC-30 were selected for inclusion. Their methodological quality was assessed with the before-after studies tool that is proposed by the National Institute of Health (NIH). RESULTS: Ten studies that involved 5181 patients were included in the present systematic review. The risk of bias and methodological quality of included studies was of good and fair overall quality. Retrieved data suggest there is substantial evidence that points toward improved global QoL among ovarian cancer patients treated with taxanes-platinum combination therapy. Individual outcomes evaluated with the QLQ-C30 also provide positive results, although underreporting was noted. CONCLUSION: Despite the significant heterogeneity in outcome reporting, the findings of this study reveal the significant benefit of combined platinum taxane chemotherapy on the QoL of ovarian cancer patients and can be used for patients counseling in order to reduce refusals that arise from fear of adverse effects that may negatively affect QoL. Graphical abstract.
PURPOSE: Chemotherapy is the cornerstone of adjuvant therapy in ovarian cancer. Its impact on the quality of life (QoL) has been addressed in several studies; however, several misperceptions concerning this affect patient counseling and physicians' ability to overcome patient fears. In the present systematic review, we sought to accumulate current evidence in the field in order to help establish robust information that will help physicians answer patients' questions. METHODS: The present systematic review is based on the PRISMA guidelines. Studies that evaluated patient QoL pre-, during, and post-chemotherapy with the use of the QLQC-30 were selected for inclusion. Their methodological quality was assessed with the before-after studies tool that is proposed by the National Institute of Health (NIH). RESULTS: Ten studies that involved 5181 patients were included in the present systematic review. The risk of bias and methodological quality of included studies was of good and fair overall quality. Retrieved data suggest there is substantial evidence that points toward improved global QoL among ovarian cancer patients treated with taxanes-platinum combination therapy. Individual outcomes evaluated with the QLQ-C30 also provide positive results, although underreporting was noted. CONCLUSION: Despite the significant heterogeneity in outcome reporting, the findings of this study reveal the significant benefit of combined platinum taxane chemotherapy on the QoL of ovarian cancer patients and can be used for patients counseling in order to reduce refusals that arise from fear of adverse effects that may negatively affect QoL. Graphical abstract.
Authors: Lori Brotto; Michael Brundage; Paul Hoskins; Ignace Vergote; Andres Cervantes; Herraez A Casado; A Poveda; Elizabeth Eisenhauer; Dongsheng Tu Journal: Support Care Cancer Date: 2015-08-25 Impact factor: 3.603
Authors: Andreas du Bois; Jørn Herrstedt; Anne-Claire Hardy-Bessard; Hans-Helge Müller; Philipp Harter; Gunnar Kristensen; Florence Joly; Jens Huober; Elisabeth Avall-Lundqvist; Béatrice Weber; Christian Kurzeder; Svetislav Jelic; Eric Pujade-Lauraine; Alexander Burges; Jacobus Pfisterer; Martina Gropp; Anne Staehle; Pauline Wimberger; Christian Jackisch; Jalid Sehouli Journal: J Clin Oncol Date: 2010-08-23 Impact factor: 44.544
Authors: Sarah P Blagden; Adrian D Cook; Christopher Poole; Lesley Howells; Ian A McNeish; Andrew Dean; Jae-Weon Kim; Dearbhaile M O'Donnell; Jane Hook; Elizabeth C James; Ian R White; Timothy Perren; Rosemary Lord; Graham Dark; Helena M Earl; Marcia Hall; Richard Kaplan; Jonathan A Ledermann; Andrew R Clamp Journal: Lancet Oncol Date: 2020-07 Impact factor: 41.316